Previous studies have demonstrated that combining siRNA targeting E6/E7 with cisplatin or radiation therapy can restore TP53 and RB/E2F, resulting in improved therapeutic outcomes for cervical cancer in vivo [14, 19]. The gene discussed is TP53; the disease is cervical cancer.